at 5 years to < 10%. The rationale of radiotherapy to the whole breast includes eradication of multifocal areas of duct carcinoma in situ (DCIS). However, the radiosensitivity of DCIS is unknown. A retrospective analysis has been performed in patients who have breast recurrence after lumpectomy +radiotherapy for early stage breast cancer. The incidence of DCIS in relapsed patients has been investigated in terms of initial primary histology and whether radiotherapy had been given. Biopsy specimens have been independently reviewed from patients who relapsed in the breast after local excision for 10 invasive breast cancer (10 cases), 1°invasive breast cancer with DCIS (26 cases) and pure DCIS (7 cases). All patients had been treated by complete LE (1 cm clearance) and RT was given to the whole breast (usually =60 Gy/30F/6 weeks).
at 5 years to < 10%. The rationale of radiotherapy to the whole breast includes eradication of multifocal areas of duct carcinoma in situ (DCIS) . However, the radiosensitivity of DCIS is unknown. A retrospective analysis has been performed in patients who have breast recurrence after lumpectomy +radiotherapy for early stage breast cancer. The incidence of DCIS in relapsed patients has been investigated in terms of initial primary histology and whether radiotherapy had been given. Biopsy specimens have been independently reviewed from patients who relapsed in the breast after local excision for 10 invasive breast cancer (10 cases), 1°invasive breast cancer with DCIS (26 cases) and pure DCIS (7 cases). All patients had been treated by complete LE (1 cm clearance) and RT was given to the whole breast (usually =60 Gy/30F/6 weeks).
DCIS was present in the recurrent tumour in more than one third of patients, regardless of whether radiotherapy had been given or not. On analysis, position, timing and pathology of the recurrent tumour suggests failure to eradicate original DCIS. These data suggest that high dose radiotherapy is relatively ineffective in eradicating DCIS in the vicinity of primary breast cancers and presumably elsewhere in the breast. These data question the use of radiotherapy to the whole breast after wide local excision for invasive breast cancer in the management of patients with pure DCIS treated by lumpectomy.
A randomised cross-over trial of megestrol acetate vs. tamoxifen as initial treatment for post-menopausal women with advanced breast cancer N. Stuart', C. Tyrell2, D. Spooner1, C. Keen3, A. Taylor4, J. Tarrant4, G. Blackledgel, D. Webster ' & G. Rees6 3 (9%) achieved CR, 13 (38%) PR, 10 (29%) SD and 8 (24%) PD. Ten pts have completed treatment B and of these 8 have crossed-over. Following cross-over 6 are evaluable: 1 PR, 3 SD and 1 had PD. Toxicity has occurred in only a minority of pts in both groups. In group A 5/34 pts with follow-up data experienced toxicity during first treatment (fluid retention=2 pts, glycosuria=3 pts). In group B 6/34 pts experienced toxicity during first treatment (PV bleeding=lpt, flushes=3 pts, nausea=2 pts). In all cases toxicity was mild (WHO grade 2 or less).
Interim analysis indicates that both treatments show broadly comparable response rates in post-menopausal women with advanced breast cancer. Both produce minimal toxicity. This study will continue until 200 pts have been randomised. Final end-points will include initial and crossover response rates, toxicity, time to progression and survival.
Affecting the natural history of breast cancer J.R. Harris & Samuel Hellman2 1Joint Center for Radiation Therapy, Harvard Medical School, Boston and 2Memorial Sloan-Kettering Cancer Center, New York, USA.
The many changes in breast cancer management offer an opportunity to review the hypotheses on which these are based and the evidence that such treatments affect ultimate survival. Traditional treatment has been based on the notion that the disease, in many patients, is an orderly one starting with local disease and then spreading to the regional lymph nodes and finally distantly. The alternative hypothesis is that if the disease is to demonstrate metastatic potential, it metastasizes before clinical presentation and thus local and regional treatment are of little or no value. Current evidence seems to argue against the latter hypothesis being regularly the case since breast cancer mortality can be reduced by as much as 30% using mammographic screening. Local control appears to influence the proportion of distant metastases seen in randomized control clinical trials. Even in patients with positive nodes improved local control is associated with improved survival. Systemic therapies are also available for the treatment of occult distant metastases. While evaluation is limited by the restricted follow-up time, it is clear that survival curves are altered and that survival is prolonged. What is not clear is whether the proportion of patients cured of the disease has changed. The radiation tolerance of the brachial plexus was investigated in 459 patients with breast cancer treated postoperatively. The effects of two radiation schedules were compared: 60 Gy in 30 fractions or'51 Gy in 15 fractions, both over 6 weeks. Patient follow-up was 30-58 months after radiotherapy. The incidence of neurological damage to the brachial plexus was 2.7% with large fraction size (3.4Gy) and < 1% with small fraction size (2 Gy).
Computed tomography (CT) of the root of neck and axilla, using bolus i.v. contrast to improve visualisation of the brachial plexus, was performed in 42 patients (44 CT scans). A pattern of increased soft-tissue density (ISD) surrounding the brachial plexus was interpreted as a post radiation effect, distinguishable from recurrent disease. Ninety-six per cent (27/28) of patients with a clinically detectable brachial plexus lesion had ISD, while only 50% (8/16) of patients with no neurological deficit had ISD. The pattern of ISD was not related to nodal disease status, type of axillary surgery or technique of radiotherapy. The degree of ISD (graded mild, moderate or severe) appears to be associated with large fraction size. Fifty-four per cent (17/31) of patients receiving large dose per fraction had moderate or severe ISD, compared with 23% (3/13) of patients treated with small dose per fraction.
It is concluded that CT can usefully assess the degree of post radiation effect, and that the radiation tolerance of the brachial plexus is largely dependent on fraction size. The relationship between total dose and fraction size can be calculated.
Elucidating the action of the antioestrogens? Response to toremifene (Fc-1157a) The clinical activity of the triphenylethylene group of drugs does not demonstrate an absolute correlation with their antioestrogenic activity or the oestrogen receptor content of the tumour.
Toremifene (Fc-1157a) is a new triphenylethylene antioestrogen which at low concentrations produces effects comparable with tamoxifen. At higher dose toremifene exerts anti-tumour effects, some of which are different from those of tamoxifen and are directed against oestrogen receptor negative breast tumours and tumours of mesenchymal origin. The exact mechanism of these effects is unknown.
To determine whether this effect seen in experimental cell lines and animal models is reproducible in man we have used toremifene as a second line therapy in patients who have relapsed whilst receiving tamoxifen.
In 9 patients treated for over 3 months toremifene produced a partial response in 3, (33%) and no change in 3, (33%) using UICC criteria.
A single patient with multiple desmoid tumours who relapsed after responding to tamoxifen also responded dramatically to toremifene.
As this is a group of patients who had relapsed whilst receiving tamoxifen, it may be that, as in cell culture and animal experiments, we are witnessing an alternative pathway of action perhaps mediated by effects on mesenchymal cells.
Conference Lecture
Early breast cancer trialists collaboration R. Peto Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK. Taken in isolation, most clinical trials in early breast cancer would not be capable of determining reliably whether a particular adjuvant treatment had (a) no material effect on survival, or (b) a moderate yet humanly worthwhile effect (e.g. reducing 5-year mortality from 1/3 down to 1/4). An overview of all available randomised trials might, however, be accurate enough for this purpose, and a large number of trialists have therefore chosen to collaborate in such an overview. Some of the main results from this collaboration will be presented on their behalf. Among women aged over 50, 2 years of tamoxifen reduced 5-year mortality from 33% to 25%, an effect that was overwhelmingly statistically significant. Among women under 50, however, the number of women available for review was smaller, and no direct evidence of an effect of tamoxifen on mortality existed, either because it has little effect on mortality or because the results were distorted by the play of chance. For polychemotherapy, the opposite pattern was apparent: it produced a highly significant mortality reduction among women under the age of 50, but a smaller and less clearly significant effect among older women. For both agents, the proportional changes in outcome appeared similar for women with no, few or many axillary nodes. The effects on longterm survival after 5 Alternating courses of cytotoxic chemotherapy and hyperfractionated radiotherapy may improve the therapeutic ratio in LDSCLC. Fourteen patients were entered in to a feasibility study of hyperfractionated radiotherapy intercalated between courses of induction chemotherapy. WHO performance status at presentation was 0 or 1 in all patients. Median age at presentation was 61 years, range 50-69. Five courses of JM8 (400mgm 2 day 1), Ifosfamide (5gm-1 day 1), VP16 (lOOmgm-2 days 1-3) were given at 28 day intervals. Five days after the first and second courses of chemotherapy a 5 day course of radiotherapy was given to the primary tumour and mediastinum by AP opposed fields using 5 Mev X-rays. Each course of radiotherapy delivered 15 Gy tumour dose in 15 fractions over 5 consecutive days with a 3h gap between fractions. During the period of intercalated radio-chemotherapy, performance status remained unchanged or improved in 9/14 patients and deteriorated in 5 patients including 1 death. Six of 27 (22%) courses of radiotherapy were associated with oesophagitis (all WHO grade III); onset was the sixth day after start of radiotherapy with resolution within 8 days. Eight of 14 patients have been followed up for a minimum of 2 months following completion of radiotherapy and 4 have radiological pneumonitis (1/4 has clinical pneumonitis). In conclusion, the incidence and severity of oesophagitis and pneumonitis are higher than expected and may reflect enhancement by high dose cytotoxic agents, especially ifosfamide. Tumour response rates are high and the protocol continues but with limited scope for escalating the radiation dose.
Chemotherapy for cerebral metastases in small cell carcinoma of the lung (SCCL) Within a chemotherapy trial for SCCL, patients with cerebral metastases were identified as a special sub-group. By withholding cranial irradiation the aim was to evaluate the effect of chemotherapy as initial treatment for cerebral metastases. Responses were objectively assessed by a series of CT brain scans.
Twenty-five patients (4.1%) had CT proven cerebral metastases at presentation, but 5 underwent cranial irradiation, and 2 craniotomy prior to chemotherapy. The remaining 18 patients were treated with cyclophosphamide 1 gm-2 i.v. day 1, vincristine 2mg i.v. day 1 and etoposide 100mg t.d.s. p.o. days 1-3, q3w. Steroids were given where clinically indicated at the lowest possible dose.
Nine of 14 patients who had a repeat CT scan achieved a CR or PR. One of the 4 clinically assessable patients also improved, giving an overall response rate of 54%. Radiological responses were rapid, sustained, accompanied by clinical improvement and included 7 patients who had not received steroids.
Chemotherapy has previously been discounted as treatment for cranial metastases because of the assumption that the blood brain barrier (BBB) protects them from systemic chemotherapy. In fact metastases develop their own tumour circulation which probably has no BBB. In SCCL cerebral metastases respond to chemotherapy which may be considered for first-line palliative treatment, having several advantages over radiotherapy. relapse, either to receive further chemotherapy (doxorubicin 50 mg m 2, and methotrexate 50 mg m-2, every 3 weeks) or symptomatic treatment alone.
Response rates to short (S) and long (L) initial chemotherapy were similar (S=61%, L=63%), as were response rates to relapse chemotherapy (S=25%, L=18%). Overall median survival (MS) from course one was analysed by intention to treat, and patients randomised to 8 courses of initial chemotherapy had a slightly longer MS than those randomised to 4 courses (MS, 39 vs. 32 weeks, P=0.085). Progression free interval (PFI) after initial chemotherapy was longer in patients receiving 8 rather than 4 courses (Median, 31 vs. 23 weeks, P=0.0002). Survival from relapse was longer for patients receiving relapse chemotherapy than for those receiving symptomatic treatment alone (MS, 17 vs. 12 weeks, P= 0.0004). Patients who received short course chemotherapy, and no further chemotherapy at relapse, clearly survived for a significantly shorter time than the other three treatment groups.
Long-term follow-up of 72 patients given prophylactic cranial irradiation for small-cell lung cancer The radiation response of 12 cell lines derived from a variety of human tumours has been investigated over the dose-rate range from 150 to 1.6 cGy min -1. As the dose-rate was lowered, the amount of sparing varied widely; in two cell lines it was zero, in the other cell lines the dose required for 10-2 survival ranged up to twice the value at high dose-rate.
Low dose-rate irradiation discriminates better than high dose-rate between tumour cell lines of differing radiosensitivity. The data are equally well fitted by two mathematical models of the dose-rate effect: the LPL model of Curtis and the Incomplete Repair model of Thames. Analysis by the LPL model leads to the conclusion that the theoretical radiosensitivity in the total absence of repair was rather similar among the 7 cell lines on which this analysis was possible. What differs among these cell lines is the extent of repair and/or the probability of direct infliction of a non-repairable lesion. Recovery from radiation damage was also examined by split-dose experiments in a total of 17 human tumour cell lines. Half-time values ranged from 0.36 to 2.3 h and there was a systematic tendency for split-dose halving times to be longer than those derived from analysis of the dose-rate effect. This could imply that cellular recovery is a two-component process, low-dose rate sparing being dominated by the faster component. The actuarial 5 and 10 year survival was 77% and 65% respectively, with 56% and 49% 5 and 10 year disease-free survival. Although many factors affected the disease-free survival, the only major prognostic indicator for survival was age.
Lymphomas and leukaemia
Ninety-one patients were initially treated with combined chemotherapy and radiotherapy (CMT Seventy-four patients with lymphoblastic lymphoma have been treated by bone marrow transplantation in complete remission of disease, 27 by allogenic transplant and 47 by autograft. All of the allografted patients were conditioned using a total body irradiation (TBI) containing regimen, but TBI was used in only 13/47 in the autograft group.
At the time of analysis 49 patients were alive, 18/27 (67%) in the allograft group and 31/47 (66%) in the autograft group. Six patients died during the procedure, 3 (11%) of the allografts and 3 (6%) in the autograft group. Nine (33%) of those allografted developed GVHD assessed as Grade II or greater.
Relapse of disease was the principal cause of death in both groups. Patients transplanted in first CR had a disease free survival advantage over those transplanted in subsequent CR.
The source of marrow, whether autologous or allogenic, was found not to influence overall survival or probability of relapse. Fourteen had CNS involvement at the time of diagnosis and of these 3 still had CNS involvement at the time of ABMT. Ten further patients had CNS involvement at relapse so that 13 patients had CNS disease at the time of ABMT.
Fifteen of 24 (62.5%) achieved or maintained complete remission (CR) post ABMT. Of these, 9 patients were in CR at the time of ABMT and 2 (22%) have subsequently had CNS relapse. The remaining 7 patients remain alive and disease-free at 3-28 months post ABMT. Of 13 patients who had CNS involvement at the time of ABMT only 4 (30%) remain alive at 23-68 months post ABMT.
The overall survival of the 24 patients is not different from that of the total NHL group (P=0.67). Those patients who had CNS disease at the time of ABMT have poor survival. Side effects were more severe than expected from pilot studies with frequent stomatitis, nausea and infection.
Advanced and recurrent cervical cancer -Active chemotherapy Thirty-five evaluable patients with recurrent or disseminated cervical cancer were entered into a prospective trial of bleomycin (30 mg infused over 24 h), followed by cisplatinum (50mgm-2 bolus) and ifosfamide (5 gm-2 infused over 24h), with concomitant hydration (total 101 over 3 days) and mesna (8 gm 2 given during and for 12 h following ifosfamide). Patients received between 1 and 8 courses (mean = 4.3). Twenty-seven of 35 had previously received radiotherapy (RT).
Twenty-five (72%) objective responses were seen. Seven women had a CAT span complete response. Most patients noted a subjective improvement in disease related symptoms. Seven patients went onto further RT to consolidate the response. Response duration to date varies between 6 and 35 weeks with chemotherapy alone, 7 patients having a continuing response. All patients experienced alopecia and nausea/vomiting. Fifteen (43%) needed one or more blood transfusions, 6 (14%) developed a septicaemia, 7 (20%) developed grade 1 or 2 ifosfamide encephalopathy, 2 patients developed renal damage and there was 1 death from septicaemia.
Twelve further patients with advanced disease have been treated in a neo-adjuvant setting prior to RT, 70% having a > 50% reduction in tumour size within 2 courses. These data indicate that BIP may be used for effective palliation and debuling in around 70% of patients with advanced or recurrent cervical cancer. A multi-centre randomised trial has been launched to determine whether neoadjuvant BIP improves survival in patients with inoperable cervical cancer. Forty-six high risk patients with ovarian carcinoma were treated by intensive combined modality therapy. Thirty-three patients had TAH/BSO completed and after surgery 21 patients had bulky residual disease. All 46 patients received combination chemotherapy with cis-platinum and cyclophosphamide following surgery and 18 patients had complete abdomino-pelvic radiotherapy. Thirty-eight patients (65%) were in complete remission including 10 patients who had pathological CR. Overall response was 78% and 55% of patients were alive at 30 months.
Toxicity of the intensive combined modality therapy is reviewed. Data on haematological, GI tract, renal and hepatic toxicities are presented. In all 18 patients who had had all 3 treatment modalities, the toxicity was moderate but tolerable. There were no toxic deaths related to treatment.
Intensive combined modality therapy is necessary in high risk patients to improve results, both in terms of local control and survival, but toxicity from such therapy should be borne in mind. Pelvic dosimetry in intracavitary therapy has always been a problem because of difficulties in identifying easily the position of individual organs and of expressing dosage to them in view of the inhomogeneity of the exposure. As a compromise ICRU 38 defined bladder dosage by reference to the post wall of a Foley catheter balloon. Previous data from this hospital demonstrated that there was no correlation between this ICRU bladder reference dosage and the maximum dose to the posterior bladder wall in patients undergoing intracavitary therapy. This study defined a vertical plane through the upper vaginal applicator in which the maximum bladder base dosage was likely to occur. Subsequent studies failed to find any correlation between the distance from the mid plane of the vaginal ovoids and the posterior bladder wall and (1) Genes coding for proteins which confer multiple drug resistance and the ability to repair DNA alkylation lesions provide the cancer cell with the means to subvert intervention by many antitumour drugs. Similarly, amplification of genes coding for the protein structures of vital enzymes (e.g., dihydrofolate reductase or thymidylate synthetase) provide the cancer cell with the ability to develop resistance to drugs targeted to these enzymes, and others. A similar outcome is likely to frustrate the efforts of drug designers developing new generations of agents targeted to oncogene protein products (e.g. growth factors and growth factor receptors).
A new strategy for drug development will focus on the design of agents which can recognise, in a sequence-specific manner, key oncogene nucleotide sequences and either silence the transcription of the gene or inhibit translation of the messenger RNA sequence. The structures of prototype molecules in this new class will be discussed and prospects for success of this strategy reviewed. The Cancer Research Campaign has established a programme with the resources to bring novel drug moieties into clinical trial: these new moieties will be selected on different biological criteria than hithertofore. Thirty-two had completed their growth before endocrine assessment. Fourteen who had received spinal irradiation had a mean final standing height standard deviation score (SDS) of 1.82 below the mean for the normal population and mean final sitting height (reflecting spinal growth) SDS -2.94. Eighteen treated with cranial irradiation alone had a final height SDS of -0.94 and final sitting height SDS of -1.21. Hence spinal irradiation has a slightly significant effect on final height.
Brain tumours
Low height velocity, reflecting the rate of growth, was observed in 94 children followed prospectively, and growth hormone insufficiency (in response to insulin induced hypoglycaemia) was found in 83 of 85 children assessed. The incidence of growth hormone insufficiency is clearly higher than has previously been reported.
Forty children were treated with growth hormone and all responded with improved height velocity. Delay in instituting treatment in growth hormone deficient children leads to an irreversible loss of final height prognosis. Prospective followup and early intervention are essential to achieve a normal final adult height. Current teaching would lead us to believe that most if not all tumours have a pH lower than that of normal tissue. Studies using new techniques, e.g., magnetic resonance spectroscopy, have challenged this belief. We studied regional cerebral pH using 2 independent techniques. Using positron emission tomography and continuous inhalation of 11CO2 we measured regional cerebral pH in 12 patients with intracranial tumours. This technique allowed us to determine the intracellular pH of both normal and neoplastic brain in a virtually non-invasive fashion. Regional pH in 8 out of 12 tumours was higher than that of normal brain. Mean regional tumour pH for the group as a whole (7.03 + 0.07) did not differ significantly from that of contralateral cortex (7.00+0.05). Five patients had pH electrode measurements during craniotomy, 2 out of 5 patients had a tumour pH higher than normal brain, though mean regional tumour pH was not significantly elevated for the group as a whole. There is now evidence to suggest that not all tumours are at a pH lower than that of normal tissue. Admittedly the newer techniques involve mean measurements for a volume of more than a cubic centimetre. In future rather than assuming all tumours to be acidic it may be important to establish the pH of individual tumours or different tumour types. This would allow specifically tailored treatment to be given that would exploit any difference in pH to the full. Thirty-five patients presenting with epilepsy alone and a non-enhancing low density lesion on the CT scan underwent computer-assisted CT-guided multiple stereotactic biopsies with stereotactic angiographic control. There was no mortality or morbidity in this series and the diagnostic yield was 97%. Thirty-four patients had low grade intra-axial neoplasms. After an estimation of the pathological extent of the tumour, 3 patients underwent a computer-assisted stereotactic laser resection and 28 patients had radiotherapy.
Multiple serial biopsies offer a method of estimating the pathological boundaries of the tumour in three dimensions. Once these boundaries are known a more rational decision can be made regarding the feasibility of the total versus partial surgical resection of low grade intra-axial neoplasms and can be helpful in planning radiotherapy.
It is current clinical practice to reduce the total therapy dose as the length of spinal cord irradiated is increased. The early clinical findings of Boden (1948) We have previously described a relationship between sensitivity in vitro to CCNU or procarbazine (PCB) and RFI in patients with malignant glioma. We report here a larger series with more extensive follow-up. One hundred and fiftyseven patients (63 with grade III and 94 with grade IV gliomas, age range 18-76) were treated with PCB (100mgm-2, p.o. days 1-10), CCNU (80mgm-2, p.o., day 1) and vincristine (VCR, 1.5mgm2, i.v. day 1) following surgery and a course of adjuvant radiotherapy. Chemotherapy was administered in 12 cycles at 6 weekly intervals. Samples were taken at surgery from 56 patients, cultured and the chemosensitivity obtained to each drug using a 35S-methionine uptake assay. By comparison of the ID50 obtained for each drug to a large training set of cultures derived from malignant gliomas it was possible to designate each patient's culture as either sensitive or resistant to each of the drugs used clinically. Those with cultures which were sensitive in vitro to PCB and/or CCNU had a more favourable prognosis than those whose cultures were not (Lee-Desu Statistic= 19.2; df= 1; P<0.0001). Such a chemosensitivity test may be useful in selecting chemotherapy for patients with glioma. Only complete responses of the tumour were scored together with severe skin reaction which was associated with the formation of a black eschar.
With increasing doses of photofrin II and increasing doses of light irradiation complete tumour response steadily increased. This was, however, almost paralleled by the incidence of skin necrosis suggesting that there is a relatively low therapeutic ratio for superficial skin illumination in photochemotherapy. Skin necrosis caused little or no discomfort to patients, however, and eventually healed in all cases.
The use of interstitial light delivery by implantation of optical fibres has been initiated to try and improve the therapeutic ratio and this may also increase the range of lesions amenable to treatment.
Induction of necrosis in an experimental mouse lymphoma using modifiers of tumour oxygenation and a bioreductive drug. Vascular function has been assessed in the SaFA murine sarcoma using a fluorescent dye perfusion technique. Hoechst 33342 was injected i.v. into tumour-bearing mice and allowed to circulate for 1 min. After sacrifice, tumours were removed, frozen and sectioned at 6 Hm. The distribution of Hoechst dye was assessed by Chalkley point counting of sections viewed microscopically under epi-fluorescence. Sections were also stained using the immunofluorescent technique with an antibody to mouse laminin to delineate the basement membrane of tumour blood vessels, allowing the estimation of total vascular volume. Using these techniques we examined the effects of chemotherapy, in rhe form of combined melphalan and misonidazole (MISO), as well as varying single doses of X-rays (10-40 Gy), and attempted to correlate vascular effects with tumour response in terms of regrowth delay.
A combination of melphalan and MISO which induced a 2 week growth delay also caused a profound decrease in effective vascular volume within 24h after treatment. This vascular effect was shown to be largely due to the MISO, although MISO alone did not affect tumour growth. Doses of X-rays which induced a growth delay similar to that from the combined drugs did not decrease vascular volume significantly at any time after treatment, as assessed by Hoechst perfusion alone.
We conclude that the contribution of vascular collapse to tumour growth delay may vary with different forms of therapy.
Rectal tumours
External beam radiotherapy for rectal adenocarcinoma R.E. Taylorl, G.R. Kerrl Thirty-seven patients with T3b, T4, N2 or N3 advanced local breast cancer were treated with 3-6 cycles of vincristine 1.4mg m 2, doxorubicin 40 mg m-2 and cyclophosphamide 600 mgm-2 i.v. with an overall response rate of 67%.
Fourteen patients had received a trial of hormone therapy, but no patient had been given prior cytotoxic chemotherapy or radiation therapy. In no case was chemotherapy discontinued on account of toxicity. Where gross disease remained (>3 cm), mastectomy (10 patients) or local excisions (5 patients), was carried out, and 32 patients then received radiotherapy, 57Gy in 24 fractions to the breast with boost to the tumour site. Complete clinical remission was achieved in 19% of patients after chemotherapy, in a further 30% after surgery, and in a further 27% by radiation therapy, giving an overall remission rate of 86% and a total complete remission rate of 76%. Of the 10 patients with N3 disease, half were dead within 1 year. The survival rate in the entire group was 50% at 2 years. The median time to relapse in the 28 complete responders was 17 months. Local palliation, defined as absence of pain, ulceration or an enlarging mass was achieved in 92% of the total number of patients, and in 60% of the patients surviving 2 Published data suggest that factors predicting poor response and survival exist in patients starting chemotherapy for advanced disease. In our own multivariate analysis, interval of under two years from diagnosis (P=0.006) and presence of visceral metastases (P=0.029) were significant. It may be appropriate to reserve aggressive combination chemotherapy for patients exhibiting poor prognostic factors.
This trial separates patients with objectively assessable disease into groups: a 'high-risk' group below age 70 years with visceral metastases or an interval of under two years between diagnosis and starting chemotherapy, and a 'lowrisk' group of patients falling outside these criteria. To be accepted, patients must be off hormone therapy and must not have had previous chemotherapy. The 'high-risk' group are randomised between epirubicin, mitozantrone and Endocrine or chemotherapy is widely used in the treatment of advanced breast cancer. In order to improve the relatively constant response rates to such therapy, however, it has been proposed that endocrine and chemotherapy should be combined and we are currently investigating the use of cyclical sequential hormonochemotherapy (CySHoC). Hormone therapy was initiated with ethynyloestradiol (10,ugday-1) for 1 week after which patients received medroxyprogesterone acetate (500mgday-1) for 2 weeks. At the end of the first 3 week period patients received a bolus injection of vincristine (2mg) and an infusion of adriamycin (50mg). The hormone therapy was then repeated after which an infusion of cyclophosphamide (500 mg), methotrexate (50 mg) and 5-fluorouracil (500 mg) was given. This treatment formed 1 double cycle and patients received 3 double cycles of CySHoC in all. So far 34 out of 40 patients with advanced breast cancer entered into this trial, irrespective of ER status, and completed 3 double cycles of CySHoC (85%). Of these 34 women, 16 (47%) showed a complete response, according to UICC criteria, 15 (44%) a partial response with only 3 (9%) failing to show any response. The disease free interval for patients showing a complete response (22+7 months) was significantly longer (P<0.001) than for those showing only a partial response (5 + 4 months).
It is concluded that the use of cyclical sequential hormonochemotherapy may offer significant advantage for the treatment of advanced breast cancer than the use of endocrine or chemotherapy alone. Anthracycline acute and chronic toxicity depends upon the peak plasma dose of the drug, whilst response rate appears to be independent and may be improved by prolonged exposure to low doses.
Infusion therapy has previously been considered difficult. However, by inserting Hickman catheters and maintaining them without routine dressing and only flushing them weekly with normal saline, we have reduced both cost and time. Rather than heavy, expensive mechanical pumps, infusions through the catheters have incorporated 'Travenol Infusors'. These are small, light disposable cylinders. Both the force to propel and a reservoir for the solution are provided by an elastomeric balloon.
To determine the merits of this method we are conducting a randomised trial of weekly epirubicin, given either by 24h infusion or bolus injection. Twenty-five postmenopausal patients (age range 63-90 years, mean 73 years) with locally advanced breast cancer (stage III and IV) were treated with a high dose of tamoxifen of 100mg daily for a week, followed by a maintenance dose of 40mg per day. Compliance was 100%. Tumour tissue from 14 of the 25 patients (56%) was assayed for hormone receptors. The diagnosis was confirmed on a Trucut biopsy. Each patient had a full blood count, biochemical profile, a chest X-ray, ultrasound scan of liver and a bone scan.
At two weeks follow up 8 patients (32%) showed a good response (-50% decrease in tumour size), 9 patients (36%) showed a moderate reponse (-25% decrease in tumour size), but 7 patients (28%) showed a poor or no response. The patients were followed up for a period of 4 months to two years (mean 9.6 months). Seven patients who had not responded at two weeks, did not show any response at 2 years follow-up and in 3 of these 7 non-responders the tumour size increased.
The high dose regimen may help to differentiate early the group of patients who are unlikely to respond to tamoxifen so that they can be treated by an alternate method early rather than late. Twenty-four patients with small cell lung cancer (SCLC), none of whom had received prior anthracycline treatment, were given Epirubicin as a single agent. In 14, an initial dose of 50 mg m -2 was used ('low dose'); the others received 100mgm-2 ('high dose'). Cycles were repeated at threeweekly intervals with a dose escalation of 25 mgm-2 for the second or subsequent cycles when deemed clinically appropriate.
Response was assessed by WHO criteria and is tabulated below: Grade 3-4 toxicity was seen in 12 patients (6 from each group) being due mainly to alopecia (all 12 patients) and thrombophlebitis (6 patients). Gastrointestinal toxicity of this grade was only seen in the 'high dose' group: persistent nausea and vomiting in 2 patients and severe mucositis in 1 patient. On no occasion did treatment have to be delayed or adjusted because of myelosuppression.
The degree of toxicity is acceptable, particularly at the 'low dose'; however the overall response rates indicate that epirubicin is an effective agent against SCLC only at doses at or above 100 mgm-2. Recent studies of the biological properties of human lung cancer cell lines have suggested major distinctions between the neuro-endocrine small-cell carcinomas (SCC) and other tumour types (non-SCC). This study set out to investigate these properties further and examine the relationships between the cell types.
A total of 13 tumour lines were derived from patients and their morphology, biochemical profiles, intermediate filament (IF) expression, hormone production and ultrastructural features examined. All cell types were found to express endocrine peptides although this was most marked in SCC. Study of the IF showed that all cell types could express both epithelial and neural IF. In addition 3 cell lines have shown alterations in morphology and biochemical properties during successive passages to different cell types. These findings are in keeping with the concept of a common cell of origin, and may have important implications for clinical response to therapy. We have applied the same chemotherapy treatment protocol at a single centre to 64 patients with acute leukaemia using combination chemotherapy for bone marrow ablation. The response to high dose chemotherapy and ABMT and its associated morbidity and mortality have been compared in 39 patients with AML and 25 patients with ALL.
Thirty-one patients with AML were treated with ABMT during first complete remission (CR) and 22/31 (70%) remain in unmaintained remission at median follow-up of 29 months. Fourteen of 31 patients have received double grafts and all remain in unmaintained remission, median follow-up 32 months.
Twelve patients with ALL were treated in first CR. Only 3/12 (25%) remain in unmaintained remission at 15, 16 and 36 months post ABMT. Two patients in this group relapsed late after transplant at 32 and 33 months respectively.
In patients treated after first remission of disease only 2/21 (9.5%) remain disease free at 32 and 56 months post ABMT, both patients having ALL in second CR. Seventeen of 21 (81%) have died of recurrent leukaemia.
We find this protocol worthy of further study in AML in first CR, but have abandoned this approach in other groups with acute leukaemia.
Immunocytochemistry -Its value in cancer diagnosis and management
Departments of 1Histopathology and 2Radiotherapy, UMDS, St. Thomas Hospital, London, UK.
The use of immunocytochemical techniques in tumour pathology is well established, and may be essential for precise classification. With the advent of more effective treatment modalities, accurate diagnosis has become even more important for cure, for long term remission, and for effective palliation. Our interest has been predominantly in those tumours which presented with metastatic deposits and an unknown primary site. We have also studied tumours of adjacent organs such as the prostate and bladder, and the prostate and rectum, where it has been difficult on purely morphological grounds to determine the organ of origin. We are in the process of following up 140 patients whose tumours have given rise to problems in histopathological diagnosis. An immunoperoxidase technique has been used for the localisation in formalin-fixed paraffin-embedded sections of a variety of mainly epithelial markers, including carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), cytokeratin (CAM 5.2), DD9-E7, S100, and prostatic acid phosphatase. Twenty-five were deposits in bone, 20 in lymph nodes, 26 were pleural or pulmonary lesions, 11 were hepatic deposits, 31 were ?prostate ?bladder, and there were 38 from other sites. Most success was achieved in the diagnosis or exclusion of the prostate as the primary site. It was also possible to exclude certain sites such as stomach, pancreas, colon, or kidney, so avoiding unneccesary radiological and/or invasive investigations, with important implications in terms of patient management and Thirty-eight patients with advanced relapsed Hodgkin's disease have been treated by high dose chemotherapy and ABMT in our centre. There were 30 males and 8 females. The median age was 29 years. No patient had previous bone marrow involvement. Three patients had failed to achieve complete remission (CR) with first-line alternating chemotherapy (LOPP/EVAP). The remaining 35 patients had received at least two regimens of salvage therapy including localised radiotherapy in 18 patients.
Four patients died of sepsis during the neutropenic phase. Eighteen patients entered CR post ABMT, 4 further patients showed partial response and only two patients have shown no response to high dose therapy. Those who achieve CR have a significant improvement in overall survival over those who do not.
Analysis of BNLI data identifies 3 groups of patients who may benefit from ABMT. Poor prognosis patients who fail first line therapy, failure to alternate firstline therapy and failure of any two sequential modalities of therapy.
Most of our patients were grafted with disease too advanced to achieve a respectable result from ABMT. In the future it seems more appropriate to investigate the role of ABMT versus conventional therapy in poor risk patients. Primary non-Hodgkin's lymphoma of the brain is a rare disease accounting for less than 2% of intracranial tumours. It appears to behave in a far more aggressive manner than its extracerebral counterpart. Recently there have been reports of a marked increase in its incidence in immunosuppressed individuals; particularly those with the Acquired Immune Deficiency Syndrome.
The natural history and treatment of 15 cases of primary non-Hodgkin's lymphoma of the brain presenting between 1974 and 1986 is reviewed. Most cases showed a rapid response to treatment. Mean survival was only 17 months ranging from 3-55 months with 8/15 patients dying from CNS relapse and 3/15 from incontrolled systemic disease.
The role of surgery, chemotherapy and radiotherapy is discussed. The optimal treatment of this disease remains elusive and the investigation of alternative methods of treatment is warranted. An analysis was made of over 750 patients with Hodgkin's disease entered into BNLI studies over the last 15 years. These patients were pathologically or clinically staged I or II with upper half disease, with or without systemic 'B' symptoms, and were histologically graded as being LP, MC NS grade I, and NS grade II.
The disease free survival, survival from 'salvage' therapy, and the overall survival of these patients was determined, together with their relationship to various prognostic factors.
The success of both initial treatment and 'salvage' therapy was found to be related to prognostic factors, with LP and MC histology being related mainly to the presentation lymphocyte count, and nodular sclerosis to the presentation ESR, the histological grade, and the presence or absence of mediastinal involvement.
The overall survival of patients who were over 60 years of age at presentation was significantly worse than that of younger patients. Patients requiring 2nd line treatment who failed to obtain complete remission from it had an extremely poor survival. Sixty-three patients with malignant extradural tumours of the spine have been treated surgically for spinal cord compression or uncontrolled back pain. Anterior surgery was used in 37 cases, posterior surgery in 22 cases, and in 4 cases combined or staged anterior and posterior decompression. The medical oncologists were involved in the assessment of the patients on presentation and adjuvant therapy was used post-operatively where this was considered appropriate.
Anterior surgery showed major neurological recovery in 54.5% of cases; only 12.1% of patients remained unchanged; the remaining patients improved neurologically but not sufficient to allow them to walk or to regain bladder function. posterior surgery achieved major neurological recovery in 33.3% of cases; over 44% were unchanged.
Back pain was improved in 73% of those undergoing anterior surgery, and 54% after posterior surgery. The complication rate was similar for the two groups. Five patients died from surgical complications; 36 had died with disseminated carcinoma at the time of review; mean survival in this latter group being 4.1 months. Twenty-two patients are still alive with 17 satisfactory with a mean survival of 14.2 months. Surgery did not give major improvement in the patients presenting with complete paraplegia. One-hundred and twelve children (47 girls and 65 boys) treated for brain tumours were studied to assess the prevalence of endocrine disorders other than growth hormone deficiency. All had tumours remote from the hypothalamus or pituitary and were clinically disease free at the time of the study. All had received cranial irradiation, 73 spinal irradiation and 34 adjuvant chemotherapy. Cytotoxic agents were lomustine, vincristine and methotrexate. Mean age at treatment was 6.7 years (1-15). Mean follow-up postradiotherapy was 8.5 years.
Thyroid dysfunction was identified in 29%. Twenty-nine had elevated basal serum TSH concentrations with mean total serum thyroxine of 76.3 nmol l-1(10-118). Four had secondary hypothyroidism. There was a highly significant association between exposure to chemotherapy and elevated basal serum TSH concentrations, P<0.001, and a less significant association with spinal irradiation alone, P<0.05.
Primary gonadal dysfunction was found in 17%, 16 girls and 4 boys. Ovarian damage was associated with spinal irradiation and with a younger age at treatment. Primary testicular damage was only associated with chemotherapy particularly lomustine. Hypogonadotrophic hypogonadism was rare (6%).
ACTH deficiency was found in 4 out of 85 children assessed. Dexamethasone is thought to exert its beneficial effect by reducing perifocal oedema in patients with brain tumours. Clinical improvement, however, commonly occurs before there is any detectable decrease in perifocal oedema. Recent magnetic resonance imaging studies failed to show any decrease in peritumour oedema after the administration of dexamethasone, despite obvious clinical improvement. We set out to see if there was any circulatory cause for this improvement Using positron emission tomography we measured regional cerebral blood flow (rCBF) and regional cerebral blood volume.(rCBV) in 10 brain tumour patients within 5 days of starting dexamethasone. Regional CBF and rCBV both decreased in a coupled fashion. The mean decrease in rCBF for the whole brain was approximately 15% and the mean decrease in rCBV for the whole brain was 13%.
We think that the initial beneficial effect of dexamethasone is partly mediated through vasoconstriction of cerebral vasculature. Glucocorticoids may cause vasoconstriction by inhibiting the release of prostaglandins, e.g. prostacyclin (a potent vasodilator) from vascular endothelial cells. The magnitude of the clinical response, however, depends very much on the brain tissue compliance of individual patients. The place of chemotherapy in advanced progressive thyroid cancer is controversial and there are few reported series of its efficacy in this setting.
Twenty-nine patients with primary carcinoma of the thyroid have been treated with sequential chemotherapy regimes using the single agents etoposide, carboplatin, cisplatinum or methotrexate and the combination of adriamycin, bleomycin and vincristine (ABC). Indications for chemotherapy were symptomatic recurrent or metastatic disease from follicular, papillary or medullary carcinomas unresponsive to conventional treatment, or advanced anaplastic carcinomas. A total of 60 individual drug exposures have been evaluated in these 29 patients.
Fourteen of 29 patients (48%) responded to one or more agents: 4/22 responded to etoposide, 2/9 to carboplatin, 5/13 to cis-platinum, 1/3 to methotrexate and 5/13 to ABC. One complete response was seen following etoposide. Significant drug toxicity occurred in 8 patients. Mean survival in responders was 19 months and in non-responders 5.4 months.
Etoposide, carboplatin, cis-platin and ABC appear to be active in advanced thyroid cancer. Useful palliation and improved survival may be achieved in responders. The results of a prospective study on the use of thyroglobulin (Tg) in the follow up of patients with differentiated thyroid cancer are presented. Those When patients receiving radiotherapy treatment to the head and neck region have exposed amalgam dental fillings significant dose perturbations may be caused. These will result in small zones of high and low dosage and can result in significant mucosal reactions. Dose distributions have been measured for 5MV and for Co-60 beams using film and ionisation chamber techniques, to identify the magnitude and the range of the effects. The results show the range to be of up to 3 mm and the magnitude of the perturbed dose to lie between 0.8 and 1.8 times the unperturbed dose. Initially location devices were prepared by the dental department, using acrylic material, but the effort involved, bulk and lack of final flexibility were limiting factors. Latterly we have used a simpler technique. A thermoplastic mould is prepared with the patient holding a wide open mouth position. A fixing tray is attached to this shell and the intraoral applicator mounted, in its own separate support, on this tray. Warm thermoplastic is used so the clinician can angle the adaptor until satisfied with tumour cover. The adaptor sets in place with no extra intraoral bulk restricting access and a shell set removes the need for extreme delicacy in positioning each day.
The value of the technique depends on careful patient selection. Even with a large case load of intraoral malignancy, only a few patients will be suitable. Over a 3 year period, 20 were initially assessed as suitable and 12 treated, both alone and in combination with external beam radiation.
Clinical uses and results will be compared with our experience using intraoral moulds over the last 10 years. The optimal management of patients suffering from thymoma is controversial. A review of 69 patients seen at The Princess Margaret Hospital between 1958 and 1980 was undertaken to better define the role of radiation and chemotherapy.
Twenty-one patients had non-invasive tumours, 46 had invasive tumours and in two the degree of invasion could not be determined. Myasthenia gravis was present in 19 patients.
Overall survival was 63% at 5 years; relapse-free survival was 49% at 5 years. For patients with non-invasive tumours the 5-year survival was 80% and for invasive tumours 54%. Significant adverse prognostic factors included the presence of invasion, unresectable tumour and nodal metastases at presentation. The presence of myasthenia gravis did not influence survival.
Tumour recurrence in the mediastinum occurred in 20% of patients with radiation including 50% of those with unresectable tumour. Complete surgical resection, including resection of pleural metastases if present, is the appropriate initial management for patients with thymoma. Postoperative radiation therapy is indicated for invasive tumours and, combined with chemotherapy, is the primary form of management for those that are unresectable.
A prospective randomised multicentre trial of adjuvant methotrexate in T3 carcinoma of the bladder A. Horwich Co-operative Urological Cancer Group, Institute of Cancer Research, Sutton, UK.
Four hundred patients were randomised to receive local treatment (LT) alone, or LT plus methotrexate (LT+MTX) for T3 bladder carcinoma. LT was irradiation (RT) in two phases to 64 Gy in 32 fractions in 6j weeks, except in some centres where patients -65 years were treated with pelvic RT to 44Gy followed by cystectomy. MTX (100mgm-2 i.v. push with folimic acid rescue) was administered weekly for 3 weeks prior to RT, and following LT MTX dose 100mg (total) q 2 weeks for 3 months then q 4 weeks for 9 months.
Of 360 evaluable patients with F/U more than 6 months there was no significant difference in median survival between 178 patients randomised to LT+MTX and 182 to LT alone (23 vs. 17 months, P<0.1). The local recurrence rate was 30% for 146 LT+MTX patients and 28% for 151 LT patients. Eighty-five (48%) of 178 LT+MTX patients developed distant metastases compared to 86 (47%) of 182 Lt patients. There was no difference in the incidence of early side effects of treatment. It was concluded that adjuvant methotrexate was not effective in the context of this study. It is widely accepted that advanced prostatic carcinoma will respond to a reduction of circulating testosterone levels in more than 80% of cases. Various methods including bilateral orchidectomy, gonadotrophin analogues and antiandrogens are in use in our unit. Traditionally treatment response is monitored clinically and by measurement of prostatic acid phosphatase (PAP). Acid phosphatase is, however, raised prior to treatment in only 60% of cases and will be of little use on many occasions.
Prostate specific antigen is produced in the cytoplasm of prostatic cells. It can be measured in serum by an immunoradiometric assay. It is raised above the usually accepted upper limit of normal of lOngml-1 in 95% of men with metastatic prostatic cancer. Forty-two patients are being followed up with regular PSA measurement following hormonal manipulation for advanced prostatic cancer. Four patients showed no clinical response, in each case PSA continued to rise. The remaining 38 patients showed good clinical response with a fall in serum PSA levels. It is of interest that the rate of fall varied from rapidly to normal within 1 to 3 months to a more gradual fall over 6 months or more.
Serum prostatic specific antigen measurement provides a more sensitive monitor of prostatic carcinoma than either acid or alkaline phosphatase. PSA should be the main tumour marker for prostatic cancer. Seventeen patients presenting to the Testicular Tumour Unit of the RMH with malignant teratoma were studied to assess the late renal toxicity of 'BEP' chemotherapy (4-6 courses).
All had normal GFR's as assessed by EDTA renal clearance, and no evidence of obstructive uropathy or past medical history of renal disease. GFR was measured before any chemotherapy and before subsequent courses. It was also assessed in these patients who were rendered disease free 8-57 months (median 31 months) after cessation of all chemotherapy (post-treatment GFR). The mean GFR fell from 132mlmin-' (95% confidence limit 123-141) to 107 ml min-(95% confidence limit 100-114) whilst on treatment. The post-treatment GFR mean was 103 ml min-1.
Of the 17 patients, the post-treatment GFR improved by over 10% in 5 patients and continued to fall by more than 10% in 5 patients, the most notable being from a pretreatment GFR of 157mlmin-' to 116mlmin-' on treatment, to a post-treatment value of 75 ml min-two years after cessation of chemotherapy. Adriamycin, cis-platin and gamma-radiation sensitivities in vitro of continuous cell lines derived from 5 human nonseminomatous testicular germ cell tumours and 5 human transitional cell carcinomas of the bladder were compared. The range of adriamycin concentrations reducing clonogenic cell survival by 70% following continuous exposure for the testicular cell lines was 0.8-7.2ngml-1, compared with 3.6-18.6ngml-1 for the bladder cell lines, and the corresponding figures for cis-platin were 19-161 and 112-431 ng ml-1. Cisplatin binding to DNA following exposure to an equimolar concentration was identical in a bladder and a testicular line with a two-fold difference in sensitivity. There was no correlation between population doubling time and drug sensitivity. Extrapolating from the gamma-radiation survival curves, Do values for the bladder lines ranged from 1.6-2.1 Gy, compared with 1.2-1.5 Gy for the testicular lines. DNA synthesis following gamma-radiation was not inhibited in two testicular cell lines to the same extent as that in two bladder lines.
It is concluded that testicular germ cell tumours retain their characteristic sensitivity to cytotoxic agents in vitro. Consequently, drug sensitivity probably is an inherent feature of these tumour cells, and not dependent on humoral factors such as blood supply or immunogenicity. Our preliminary data suggest that testicular tumour cells may have a relatively low capacity to repair DNA following exposure to cytotoxic agents. A study of the regression of carcinoma of the bladder after radical radiotherapy was undertaken to determine whether there was any correlation between the rate of regression and the time to recurrence. This information would be useful in predicting which patients might need salvage cystectomy.
Twenty patients with carcinoma of the bladder, treated with radical radiotherapy have been studied so far. The regression of primary bladder carcinoma was measured during and after radical radiotherapy. In 12 patients the regression was determined by transabdominal ultrasound alone and in 8 patients by ultrasound and by computed tomography.
The regression of transitional-cell carcinoma of the bladder after radiotherapy is much slower than for squamous cell carcinoma of the head and neck or for carcinoma of the breast. The range of volume-halving time was 7-105 days (median 39 days). Considerable calcification occurred during the regression of some of these tumours. Thorough preoperative staging is performed and meticulous preliminary planning is required to construct a 3 dimensional model of the prostate and to calculate the number of seeds necessary to deliver a matched peripheral dose of 160Gy. Implantation is carried out under general anaesthesia using a Bruel and Kjaer 1846 transrectal ultrasound scanner with a special grid attachment which allows precise spatial distribution of seeds within the gland.
Thirty-seven patients with early disease (TO, T1, T2, No, MO) have been treated; 35 of these were well differentiated tumours. There has been no operative mortality and very little immediate morbidity and late complications are rare, but include impotence (2), incontinence (1) and perineal pain (1). Despite the high radiation dose to the prostate itself, the rectal dose is minimal in contrast to external beam therapy. An early response is commonly seen as a diminution of prostate volume. Follow up is from 4 months to 2 years. Two patients with poorly differentiated tumours have undergone disease progression.
Time in hospital is 3 days contrasting with 5 to 6 weeks for external beam therapy. Transperineal placement of 1125 seeds is a simple effective treatment for early prostatic carcinoma.
treated between 1958 and 1984 in order to define the natural history of the second tumour. There was a history of maldescent in 28% of evaluable patients, infertility in 22%, and both maldescent and infertility in 21%. The distribution of histology of the first tumour (seminoma in 17, teratoma in 11, combined tumours 3) was not significantly different from the distribution in the second tumour (seminoma 15, teratoma 8, combined 7). Additionally, there were 4 patients who presented with synchromous tumours and 2 of these had different histologies in the 2 tumours.
Twenty-nine patients had no treatment to the contralateral testis following their first orchidectomy (abdominal node irradiation in 23 patients, surveillance in 5 patients and node dissection in 1 patient). Two patients were treated with chemotherapy for their first testicular tumour. One patient received four courses of bleomycin, etoposide and cisplatinum which he completed 4y years before the presentation of his second tumour. He is disease-free one year after his second orchidectomy. The other received 6 courses of vinblastine and bleomycin which he completed 9 months before the presentation of his second tumour. He died with widely disseminated disease 14 Modification to the cardiac output in Sprague Dawley rats was assessed following the intravenous administration of single doses of epirubicin (2-10mgkg-1). Cardiac function was measured using an isotope dilution technique at 4-weekly intervals for up to 20 weeks. After a sharp initial decline in cardiac function in drug treated animals (phase I), values remained persistently depressed (phase II) indicating the irreversible nature of anthracycline-associated cardiac lesions. The duration of phase I varied from 4 to 12 weeks depending on dose. In phase II cardiac output values were relatively stable for most animals and deterioration in heart function was usually only in those rats which had shown a >40% reduction in cardiac function in phase I. There were no statistically significant differences between the mean heart rate measured in drug treated and age-matched control animals. This suggested that the reduction in cardiac function was due to the loss of contractile elements in the cardiac muscle. The 50% incidence dose (ED50) for a >30% or a > 50% reduction of cardiac output, 12 weeks after drug treatment, was 3.34 + 0.4mg kg-1 and 4.93 + 0.43mg kg-' respectively.
After the administration of single doses of adriamycin, the modification in cardiac function followed the same time course to that after epirubicin. However, adriamycin showed a greater acute effect and cardiotoxicity. Adriamycin was found to be twice as cardiotoxic as epirubicin and this was independent of the drug dose and hence the level of damage in the heart.
The management of diarrhoea and steatorrhoea due to radiation enteritis can prove troublesome. Several pathophysiological abnormalities can be involved, each requiring specific therapy. Choosing the treatment most likely to succeed in each case therefore depends on identifying which mechanism is involved. Gastroenterologists have recently developed several non-invasive diagnostic techniques which can be used to pinpoint the precise cause in each case simply and rapidly. Some of these tests -to identify di-and monosaccharide malabsorption, bile acid deconjugation, bile acid malabsorption, gut hurry and mucosal inflammation -may not be familiar to radiotherapists. An algorithm has therefore been devised in which each of the tests is arranged so as to arrive at a diagnosis with as few procedures as possible, but it has yet to be formally tested. The use of intra-arterial adriamycin as an adjunct to radiotherapy and limb conserving surgery has previously been described in an attempt to improve local control rates without amputation in the primary treatment of soft tissue sarcoma (STS). The late normal tissue damage that was described following such an approach raised concern about its toxicity, and prompted a pilot study, which is presented here, in which late normal tissue damage was specifically assessed. Ten patients with STS were treated by this trimodality approach using conventionally fractionated radiotherapy; their late normal tissue damage was compared with that in 10 patients recently treated by radiotherapy and conservation surgery without adriamycin. No significant difference in late morbidity was observed between the two groups. This approach appears safe provided conventional fractionation is employed. The late normal tissue damage seen in previous series might be accounted for by the unconventional radiotherapy fractionation employed. It remains to be proven that the addition of intra-arterial adriamycin to surgery and radiotherapy confers any benefit in terms of local control or survival.
A randomized prospective observer blind trial of E45 cream in the early skin reaction following post-mastectomy chest wall radiotherapy
M.H. Robinson
Royal Marsden Hospital, London, UK.
Management of the early skin reaction to orthovoltage radiotherapy is controversial. There are proponents and opponents of treatment with medicated and non-medicated skin creams. Use of a new formulation of E45 cream was therefore studied in patients who received post-mastectomy radiotherapy to the chest wall and/or the axilla and supraclavicular region (a mid-plane dose of 38Gy in 10 fractions over 28 days given 3 times a week).
Patients were randomised to apply E45 cream twice daily for 28 days or not at all after radiotherapy (day 0). The doctor assessed the skin reaction with 5 point scales for severity of reaction, redness, dryness, itchiness and soreness on days 0, 14 and 28. Patients kept daily records. At day 14, the physician determined whether patients needed treatment for the skin reaction. If so, this was dispensed. The group using the cream previously continued to do so.
Forty-two patients entered. Groups were comparable in the development of the skin reaction. Significant differences (P < 0.01) were found in favour or E45 cream for skin dryness in patients with constant and changed therapy. In patients with partially obstructed airways (n = 79), an overall symptomatic improvement was noted in 59 (75%), while peak flow and/or spirometry rose by at least 20% in 51 (65%). Patients with tracheal and main carinal tumours (n=49) reported the most impressive symptomatic gains and exhibited the most marked increases in peak flow (mean rise of 57%; P<0.001) and FEV1. In patients with partial obstruction of more peripheral airways (mainstem and lobar-bronchi; n = 30), symptom scores and lung function also improved significantly (P<0.01). In patients with complete endobronchial obstruction (n= 16), treatment was successful in 9 (56%); re-expansion was associated with improved symptom scores and increases in FVC, the best results being seen in patients with main bronchial obstruction (P<0.05). Haemoptysis was completely abolished in 8 patients (80%); the period of relief ranged from 3 weeks to 4 months.
We conclude that endoscopic laser treatment provides significant relief from haemoptysis and breathlessness in selected patients, and that the response in patients with breathlessness varies according to the level of obstruction. Intrathecal opiates have been administered to 6 patients with severe pain from disseminated malignant disease resistant to oral and intramuscular analgesia. The pain was mainly pelvic in origin.
The system consists of standard components of a lumboperitoneal shunt (approximately £280). Implanted under general anaesthetic a 4FG catheter is introduced by a Tuohy needle into the lumbar sac and connected to a 3.5 ml subcutaneous reservoir over the ribs, allowing percutaneous intrathecal injections. In 5 cases the patient could stop all alternative means of opiate administration, to be replaced by either OM or bd diamorphine 5-15mg in various dilutions of saline (usually 10mg in 7 ml). Three patients returned home, diamorphine being given by GP, district nurse and spouse. Two (with colostomies) required the systems removal for skin commensal meningitis at 6 and 8 weeks. The third patient's reservoir was replaced because of multiple puncture leakage at 10 weeks. The remaining patients died relatively pain-free in hospital.
A similar system was placed epidurally following the removal of the first for meningitis. It was not successful. An alternative subcutaneous system (Cordis Secor TM cost £490) is being evaluated at present. It has a measured dose pump, patient administered on demand from a reservoir holding approximately 1 month's supply of morphine.
In conclusion, a simple, cheap and effective system for pain control is presented, best for short-term use and contraindicated in colostomy patients in community care. A better but more expensive long-term system is under evaluation. The suitability of patients with sarcomas of the thigh, buttock or pelvis for HQA is usually determined by clinical examination. Our aim was to evaluate the role of CT in assessing their operability.
Ten patients were referred for HQA. Patients were considered unsuitable for HQA if on surface examination malignant disease extended into the perineum, across the sacro-iliac joint or above the inguinal ligament. Buttock tumours palpable on pelvic examination were also considered inoperable. Tumours were considered inoperable if CT showed buttock disease extending through the greater sciatic notch, the psoas muscle was involved above the inguinal ligament, the disease crossed the sacro-iliac joint or the perineal structures were involved.
Five Lymphokines are non-antibody proteins generated by lymphocyte activation; current evidence implicates lymphokines in effecting both specific and non-specific immunity. The rationale for administering lymphokines in malignant melanoma is to assist host defence mechanisms against tumour spread and to help maintain the integrity of the immune system. In this paper we review current approaches to the therapeutic investigation of lymphokines in malignant melanoma.
Rosenberg and colleagues have reported that i.v. administration of high dose interleukin-2 (IL-2) both alone and in combination with autologous lymphocytes activated ex vivo with IL-2 (LAK cells) has resulted in regression of melanoma. In our preliminary work we have used buffy-coat interleukin (BC-IL), containing several lymphokine activities including IL-2, which has so far been well tolerated. Endolymphatic administration of lymphokines and LAK cells may be particularly appropriate in melanoma which spreads primarily by lymphatic pathways. We have demonstrated clinical, radiological and histological evidence of lymph node activation following administration of BC-IL by this route.
Our experience and that of other investigators suggests that the administration of lymphokines may be of value in malignant melanoma. Protocols need to be designed to explore methods of administration in patients with disease of different stages and the administration of lymphokines as an adjunct to other forms of treatment. The monitoring of white-cell function in these patients may yield important information in the design of these protocols. The vasocactive drug hydralazine can cause substantial changes in blood flow to murine tumours. One result of these changes in the induction of close to 100% hypoxia in subcutaneous tumours, which lasts for nearly 2 h following an i.v. injection of 5mgkg-1. Induction of tumour hypoxia could be therapeutically beneficial, particularly when used with radiation and the nitroimidazole radiosensitizers. This is demonstrated with results obtained using the KHT tumour in vivo when the following treatment schedule is employed:
Sensitizer-.60 min-.X-rays-+1 min-÷hydralazine. Such a strategy will first exploit the radiosensitizing properties of the nitroimidazole, then after irradiation administration of hydralazine will induce tumour hypoxia and allow expression of the differential toxicity towards hypoxic cells known to occur with agents such as RSU 1069 and misonidazole.
This approach results in a substantial increase in the apparent efficiency of misonidazole and RSU 1069 as radiosensitizers. For example, the enhancement of tumour cell killing achieved by 100mg kg-1 misonidazole when used in combination with hydralazine is equivalent to that obtained by 1000 mg kg -1 misonidazole alone. Data collection for large trials usually involves three stages:
(1) recording data in the clinical notes; (2) filling in study forms; (3) transferring data to the unit's computer system for analysis. We are streamlining this process using an easily portable microcomputer and software developed in-house, allowing direct data collection in the clinic and transfer to our main unit computer system for detailed analysis. We use an IBMcompatible Datavue 25 portable microcomputer with 768 kilobytes of random access memory and twin built-in 3.5 inch disc drives, each with 720 kilobytes of storage. The software is written in Psion Archive, an advanced programmable database language. it is designed to be menu driven, suitable for users with no computer expertise. Data collected at the clinic are stored as a database file, with one record of 139 fields per patient. String fields are used with each data item for a particular visit concatenated to the existing string for that field. Routines have been developed which allow data to be 'sliced' out of this string appropriately. As the trials in question were under way before the computer was acquired, a facility is provided to collect data retrospectively from clinical notes.
Further software allows data to be presented as a standardised printout of all data for a patient, or data for one visit. This facilitates subsequent entry of data into the unit VAX minicomputer. The software already developed involves -70 kilobytes of programming. We are now developing protocols for direct file transfer from the Datavue to the VAX via its integral serial interface.
